Send me real-time posts from this site at my email

Patterson Companies (PDCO) Q2 Earnings Surpass Estimates

Patterson Companies, Inc. PDCO reported adjusted earnings per share (EPS) of 39 cents in second-quarter fiscal 2020, which beat the Zacks Consensus Estimate by 11.4%. However, the bottom line remained flat year over year.
Net sales in the quarter were $1.42 billion, outpacing the Zacks Consensus Estimate by 0.2%. Moreover, the figure rose 1% year over year.

Segmental Analysis
The company currently distributes products through subsidiaries Patterson Dental and Patterson Animal Health.

Patterson Companies, Inc. Price, Consensus and EPS Surprise


Patterson Companies, Inc. price-consensus-eps-surprise-chart | Patterson Companies, Inc. Quote

Dental Segment

This segment provides a complete range of consumable dental products, equipment, software, turnkey digital solutions and value-added services to dentists, and laboratories throughout North America.
In the fiscal second quarter, dental sales improved 4.1% year over year to approximately $564.6 million.
Dental Consumable
Sales in the sub-segment totaled $303.1 million, down 0.2% year over year.
Dental Equipment & Software
Sales in the segment improved 12.2% on a year-over-year basis to $188.2 million.
This segment comprises technical service, parts and labor, software support services and office supplies. Sales at the segment improved 3.2% on a year-over-year basis to $73.3 million.
Animal Health Segment

This segment is a leading distributor of veterinary supplies to clinics, public and private institutions and shelters across the United States.
In the second quarter, the segment sales declined 0.8% on a year-over-year basis to $848.2 million.
Sales at the segment were $5.9 million, down 12.8% from the year-ago quarter’s figure of $6.8 million.
Gross Margin Analysis
Gross profit in the reported quarter was $301.5 million, up 2.2% year over year. As a percentage of revenues, gross margin of 21.3%, improved 30 bps year over year.
Operating expenses in the reported quarter totaled $319.6 million, up 25.9% on a year-over-year basis.

Operating loss came in at $18.1 million, against the year-ago quarter’s operating income of $41.2 million.

Fiscal 2020 Guidance Raised

For fiscal 2020, Patterson Companies now expects adjusted earnings per share in the range of $1.36 to $1.46 (up from the prior range of $1.33-$1.43). The mid-point of the guidance of $1.41 is above the Zacks Consensus Estimate of $1.38 per share.
Our Take
Patterson Companies ended second-quarter fiscal 2020 on a strong note, wherein both earnings and revenues beat the consensus mark. The company’s Dental segment performed impressively. The company’s consistent efforts to drive profitability in its core business were represented by the performance displayed in reported quarter. Expansion in gross margin is a positive. Moreover, raised outlook for fiscal 2020 instills optimism in the stock.
A broad spectrum of products cushions the company against economic downturns in the MedTech space. We believe that a diverse product portfolio, strong veterinary business prospects, accretive acquisitions and strategic partnerships are key catalysts.
Meanwhile, declining Dental Consumable revenues remains a concern. Further, the Corporate segment performed sluggishly in the quarter under review.

Zacks Rank

Patterson Companies has a Zacks Rank #4 (Sell).

Earnings of Other MedTech Majors at a Glance

Some better-ranked stocks that reported solid results this earning season are Edwards Lifesciences EW, Thermo Fisher Scientific Inc. TMO and ResMed Inc. RMD. You can see _1link">the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Third-quarter net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%. The stock carries a Zacks Rank of 2 (Buy).

Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion outpaced the Zacks Consensus Estimate by 1.3%. The stock carries a Zacks Rank #2.

ResMed reported third-quarter 2019 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%. The stock sports a Zacks Rank of 1.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
ResMed Inc. (RMD): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Patterson Companies, Inc. (PDCO): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue